Thursday, February 18, 2016

Dr. Reddy Is Transitioning From A Pure Generic Player To An Innovator

Dr. Reddy (NYSE:RDY) is trading at a 35 percent discount to the sector average valuations. Investors are excessively concerned about the USFDA warning letter escalating into an import alert. It remains difficult to predict the future, but my calculations suggest that the potential downside is already builtinto the price. Looking at the company's record of accomplishment on the regulatory side, I strongly believe that they should be able to adequately address USFDA concerns and get......Read More